Premium
Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab
Author(s) -
Anko Mayuka,
Nakamura Masaru,
Kobayashi Yusuke,
Tsuji Kosuke,
Nakada Sakura,
Nakamura Yoshio,
Funakoshi Takeru,
Banno Kouji,
Aoki Daisuke
Publication year - 2020
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.14136
Subject(s) - medicine , nivolumab , melanoma , vagina , cervical cancer , vaginal cancer , amelanotic melanoma , parametrium , cervix , colposcopy , hysterectomy , obstetrics and gynaecology , radiology , stage (stratigraphy) , gynecology , cancer , surgery , immunotherapy , pregnancy , paleontology , genetics , cancer research , biology
Primary malignant melanomas (MM) originating from the gynecological tract are rare. They respond poorly to immunotherapy when compared with cutaneous MM. This study reports two cases. The first is of a 54‐year‐old woman with a cervical amelanotic polypoid mass who was diagnosed as having stage IB1 cervical melanoma according to the International Federation of Gynecology and Obstetrics system. At 17 months post‐surgery, a computed tomography examination revealed recurrence of a 68 mm pelvic tumor. The second case is of a 37‐year‐old woman with a 7 cm hemorrhagic mass on the vaginal wall. The patient was diagnosed as having stage IV vaginal melanoma according to the American Joint Committee on Cancer definition. Both patients received nivolumab therapy, programmed cell death receptor 1 monoclonal antibodies, and the tumors almost disappeared. These cases may add the possibility of using colposcopy with narrow‐band imaging and positron‐emission tomography to diagnose and evaluate primary MM.